Bicycle Therapeutics (BCYC) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 11.8% versus a loss of 53.4%. BioAge Labs is the larger company by market cap ($284.3 million vs $263.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | BIOA |
|---|---|---|
| Share price | $3.77 | $6.20 |
| Market cap | $263.87M | $284.33M |
| 1-day change | +1.07% | -1.04% |
| YTD return | -47.32% | -52.68% |
| 1-year return | -53.37% | +11.79% |
| 5-year return | -93.71% | — |
| EPS (TTM) | $-2.73 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $25.96 |
| 52-week low | $3.33 | $5.04 |
| Distance from 52-week high | -58.84% | -76.13% |
| Analyst consensus | none | none |
| Avg. price target upside | +151.99% | +475.14% |
| Average volume | 391.03K | 913.77K |
| Shares outstanding | 50.55M | 45.90M |
| Employees | 288 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed BCYC by 65.2 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
BCYC vs BIOA FAQ
Which is bigger, Bicycle Therapeutics or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $284.33M compared with $263.87M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or BIOA?
BIOA returned +11.79% over the past 12 months, compared with -53.37% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and BioAge Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.